북미 급성 호흡곤란증후군(ARDS) 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 급성 호흡곤란증후군(ARDS) 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • North America
  • 350 Pages
  • 테이블 수: 80
  • 그림 수: 40

>북미 급성 호흡곤란 증후군(ARDS) 시장, 원인(코로나19(COVID-19), 패혈증, 유해 물질 흡입, 중증 폐렴 등), 유형(진단 및 치료), 투여 경로(경구, 비경구 등), 최종 사용자(병원, 전문 클리닉, 재택 의료 등), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 등), 국가(미국, 캐나다, 멕시코)별 산업 동향 및 2029년까지의 예측.

북미 급성 호흡곤란증후군(ARDS) 시장

시장 분석 및 통찰력 : 북미 급성 호흡곤란증후군(ARDS) 시장

북미 급성 호흡곤란증후군(ARDS) 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 10.5%의 CAGR로 성장하고 있으며 2029년까지 7,500.48백만 달러에 도달할 것으로 예상된다고 분석합니다. COVID-19의 유병률 증가는 급성 호흡곤란증후군(ARDS) 시장 성장의 원동력으로 작용합니다.

급성 호흡곤란증후군(ARDS)은 폐로 체액이 새어들어 생명을 위협하는 폐 손상입니다. ARDS에 걸린 대부분의 사람들은 이미 외상이나 COVID-19와 같은 질병으로 병원에 입원해 있습니다. 이 증후군은 일반적으로 폐의 작고 탄력 있는 기낭인 폐포에 체액이 축적될 때 발생합니다. 이러한 체액 축적으로 인해 혈류로 도달하는 산소가 줄어듭니다. 이로 인해 장기가 정상적인 기능을 수행하는 데 필요한 산소를 충분히 얻지 못하게 됩니다. 다른 질환이 있는 사람은 촉발된 부상이나 감염 후 몇 시간에서 며칠 이내에 ARDS가 발생합니다. 사망 위험은 나이가 들면서 증가하고 질병의 심각도에 따라 증후군에서 살아남은 환자는 힘들어집니다. 폐의 막낭에 손상을 입히는 심각한 질병이나 부상은 ARDS로 이어집니다. 이러한 질병의 가장 흔한 근본 원인에는 패혈증, 유해 물질 흡입, 중증 폐렴, 머리, 가슴 또는 기타 주요 부상, 코로나바이러스감염증 2019(COVID-19) 등이 있습니다.

급성 폐 손상의 유병률과 발생률 증가, ARDS에 대한 광범위한 위험 요소, ARDS가 있는 covid-19 환자 풀의 가속화는 급성 호흡 곤란 증후군(ARDS) 시장의 원동력으로 작용합니다. 북미 급성 호흡 곤란 증후군(ARDS) 시장의 성장을 촉진할 것으로 예상되는 다른 요인으로는 대기 오염과 생활 방식 관련 질병의 증가율, ARDS를 유발하는 사고율과 외상 증가가 있습니다.

그러나 치료와 관련된 합병증, 높은 장비 및 치료 비용과 같은 요인은 북미 급성 호흡곤란증후군(ARDS) 시장의 성장을 방해하고 있습니다. 반면에 노령 인구 증가, 의료비 증가 및 시장 참여자의 전략적 이니셔티브는 북미 급성 호흡곤란증후군(ARDS) 시장의 성장에 기회로 작용합니다. 승인을 위한 엄격한 규정과 ICU 간호사가 직면한 여러 과제는 북미 급성 호흡곤란증후군(ARDS) 시장에서 직면한 주요 시장 과제입니다.

급성 호흡곤란증후군(ARDS) 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 급성 호흡곤란증후군(ARDS) 시장 시나리오를 이해하려면 Data Bridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.

북미 급성 호흡곤란증후군(ARDS) 시장

급성 호흡곤란증후군(ARDS) 시장 범위 및 시장 규모

급성 호흡곤란증후군(ARDS) 시장은 원인, 유형, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

  • 원인에 따라 북미 급성 호흡곤란증후군(ARDS) 시장은 코로나바이러스감염증 2019(COVID-19), 패혈증, 유해 물질 흡입, 중증 폐렴 등으로 세분화됩니다. 2022년에는 코로나바이러스감염증 2019(COVID-19) 부문이 시장을 지배할 것으로 예상되는데, 이 질병이 지역 전체에 퍼져 사망률이 높기 때문입니다.
  • 유형을 기준으로 북미 급성 호흡곤란증후군(ARDS) 시장은 진단과 치료로 세분화됩니다. 2022년에는 사람들이 치명적인 장애에 대한 적절한 치료를 위한 시기적절한 진단을 더 잘 알게 되면서 진단 부문이 시장을 지배할 것으로 예상됩니다.
  • 투여 경로를 기준으로 북미 급성 호흡곤란증후군(ARDS) 시장은 경구, 비경구 및 기타로 세분화됩니다. 비경구 세그먼트는 근육 내 및 정맥 내로 더 세분화됩니다. 2022년에는 FDA에서 승인한 다양한 제품과 파이프라인에 있는 제품 수가 증가함에 따라 비경구 세그먼트가 시장을 지배할 것으로 예상됩니다.
  • On the basis of end-users, the North America acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare and others. In 2022, hospitals segment is expected to dominate the market due to high technological developments in developed part of country.
  • On the basis of distribution channel, the North America acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2022, direct tender segment is expected to dominate the market as the players are taking strategic initiatives in expanding their distribution channel for worldwide supply.

Acute Respiratory Distress Syndrome (ARDS) Market Country Level Analysis

The acute respiratory distress syndrome (ARDS) market is analyzed and market size information is provided by the country, five notable segments such as cause, type, route of administration, end users and distribution channel as referenced above.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are U.S., Canada and Mexico.

Hospitals segment in the U.S. is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing government and organizational support. The hospitals segment in Canada is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. Mexico is third leading the growth of the market and hospitals segment is dominating in this country due to increasing number of new hospital infrastructure being opened due to emergence of COVID-19.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Acute Respiratory Distress Syndrome (ARDS) Treatment, is Boosting the Market Growth of Acute Respiratory Distress Syndrome (ARDS) Market

The acute respiratory distress syndrome (ARDS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

급성 호흡곤란증후군(ARDS) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 급성 호흡곤란증후군(ARDS) 시장과 관련된 회사의 초점에만 관련이 있습니다.

급성 호흡곤란증후군(ARDS)을 다루는 주요 기업으로는 Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical(ICU Medical, Inc.의 일부), ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS 등이 있으며, 국내 기업도 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 급성 호흡곤란증후군(ARDS) 시장이 가속화되고 있습니다.

예를 들어,

  • 2021년 5월, Medtronic은 SonarMed 기도 모니터링 시스템 출시를 발표했습니다. 이 시스템은 음향 기술을 활용하여 기관 내 튜브 막힘을 확인합니다. 이를 통해 회사는 제품 포트폴리오를 늘리는 데 도움이 되었습니다.
  • 2020년 7월, F. Hoffman-La Roche Ltd는 SARS-CoV-2 신속 항체 검사 출시를 발표했습니다. 이 검사는 SD Biosenseor, Inc.와 협력하여 출시되었습니다. 이를 통해 회사는 제품 포트폴리오를 확대할 수 있었습니다.

협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 급성 호흡 곤란 증후군 시장에서 회사의 입지를 강화하고 조직의 수익 성장에도 도움이 됩니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CAUSE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA

5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES

5.4 LABELING OF MODIFIED DEVICES

5.5 REGULATION IN EUROPE:

5.6 REGULATION IN INDIA:

5.7 REGULATION IN JAPAN:

6 REGIONAL SUMMARY

6.1 NORTH AMERICA REGION

6.2 EUROPE REGION

6.3 ASIA-PACIFIC

6.4 SOUTH AMERICA

6.5 MIDDLE EAST AND AFRICA

7 PIPELINE ANALYSIS

8 INSURANCE REIMBURSEMENT

8.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)

8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION

8.3 ABBOTT CODING GUIDE FOR ECMO

8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)

8.5 CERN HEALTH INSURANCE SCHEME

8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)

8.7 AMERICAN HOSPITAL ASSOCIATION

8.8 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY

9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS

9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS

9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES

9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS

9.2 RESTRAINTS

9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS

9.2.2 HIGH COST OF DEVICE AND TREATMENTS

9.2.3 LACK OF SKILLED WORKFORCE

9.3 OPPORTUNITIES

9.3.1 GROWING GERIATRIC POPULATION

9.3.2 RISING HEALTHCARE EXPENDITURE

9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME

9.4 CHALLENGES

9.4.1 STRINGENT RULES & REGULATIONS

9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES

10 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

10.1 PRICE IMPACT

10.2 IMPACT ON DEMAND

10.3 IMPACT ON SUPPLY CHAIN

10.4 STRATEGIC DECISIONS FOR MANUFACTURERS

10.5 CONCLUSION

11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE

11.1 OVERVIEW

11.2 DIAGNOSIS

11.2.1 IMAGING TESTS

11.2.1.1 CHEST X-RAY

11.2.1.2 CT SCAN

11.2.1.3 ULTRASOUND

11.2.1.4 OTHERS

11.2.2 BLOOD TEST

11.2.3 RESPIRATORY RATE

11.2.4 SPO2 TEST

11.2.5 OTHERS

11.3 TREATMENT

11.3.1 MECHANICAL VENTILATION

11.3.1.1 HIGH-FLOW NASAL O2

11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE

11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE

11.3.1.4 PRONE POSITIVE VENTILATION

11.3.1.5 OTHERS

11.3.2 CORTICOSTEROIDS

11.3.2.1 METHYLPREDNISOLONE

11.3.2.2 DEXAMETHASONE

11.3.2.3 OTHERS

11.3.3 ANTIVIRAL MEDICATION

11.3.3.1 REMDESIVIR

11.3.3.2 COMBINATION DRUGS

11.3.3.3 OTHERS

11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

11.3.5 TOCILIZUMAB

11.3.6 OTHERS

12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.2.1 INTRAVENOUS

12.2.2 INTRAMUSCULAR

12.3 ORAL

12.4 OTHERS

13 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE

13.1 OVERVIEW

13.2 CORONAVIRUS DISEASE 2019 (COVID-19)

13.3 SEPSIS

13.4 INHALATION OF HARMFUL SUBSTANCES

13.5 SEVERE PNEUMONIA

13.6 OTHERS

14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 OTHERS

15 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 HOSPITAL PHARMACY

15.4 RETAIL PHARMACY

15.5 ONLINE PHARMACY

16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GILEAD SCIENCES INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUS ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 TERUMO CORPORATION

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUS ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 GETINGE AB

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUS ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 LIVANOVA PLC

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MEDTRONIC

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENTS

19.6 ALUNG TECHNOLOGIES, INC

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ARMSTRONG MEDICAL

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 BESMED HEALTH BUSINESS CORP.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENTS

19.9 DRÄGERWERK AG & CO. KGAA

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 EUROSETS

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 F. HOFFMANN-LA ROCHE LTD

19.11.1 COMPANY SNAPSHOT

19.11.2 RECENT ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 FISHER & PAYKEL HEALTHCARE LIMITED

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 FRESENIUS SE & CO. KGAA

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUS ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENTS

19.14 HAMILTON MEDICAL

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NIPRO

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUS ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 PFIZER INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUS ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 RESMED

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 SMITHS MEDICAL

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUS ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA CORONAVIRUS DISEASE 2019 (COVID-19) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 46 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 54 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 55 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 57 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 58 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 CANADA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CANADA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 CANADA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 66 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 70 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 MEXICO DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 MEXICO IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 78 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 79 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 80 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 11 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

FIGURE 15 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021

FIGURE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 17 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 18 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 20 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 21 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 23 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021

FIGURE 24 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2020-2029 (USD MILLION)

FIGURE 25 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)

FIGURE 26 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021

FIGURE 28 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 29 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021

FIGURE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 35 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2021)

FIGURE 36 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021)

FIGURE 37 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE (2022 & 2029)

FIGURE 40 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The North America Acute Respiratory Distress Syndrome (ARDS) Market size will be worth USD 7,500.48 million by 2029.
The North America Acute Respiratory Distress Syndrome (ARDS) Market growth rate will be 10.5% by 2029.
The Increasing prevalence and incidence of acute lung injury, wide range of risk factors for ARDS and acceleration in patient pool of covid-19 with ARDS are the growth drivers of the North America Acute Respiratory Distress Syndrome (ARDS) Market.
The cause, type, route of administration, end users and distribution channel are the factors on which the North America Acute Respiratory Distress Syndrome (ARDS) Market research is based.
The major companies in the North America Acute Respiratory Distress Syndrome (ARDS) Market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical (part of ICU Medical, Inc.), ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS.